BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy

BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy

Zinc(II)-dipicolylamine (Zn-DPA) has been shown to specifically identify and bind to phosphatidylserine (PS), which exists in bulk in the tumor microenvironment. BPRDP056, a Zn-DPA-SN38 conjugate was designed to provide PS-targeted drug delivery of a cytotoxic SN38 to the tumor microenvironment, the...

Full description

Bibliographic Details
Main Authors: Yun-Yu Chen, Chen-Fu Lo, Tai-Yu Chiu, Chia-Yu Hsu, Teng-Kuang Yeh, Ching-Ping Chen, Chen-Lung Huang, Chung-Yu Huang, Min-Hsien Wang, Yu-Chen Huang, Hsuan-Hui Ho, Yu-Sheng Chao, Joe C. Shih, Lun K. Tsou, Chiung-Tong Chen
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Subjects:
BPRDP056
Dipicolylamine
Phosphatidylserine targeting
Drug conjugate
Drug delivery
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320303892

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320303892

Similar Items